Lung Cancer

Click on the tabs above by lung cancer type to view active trials.
Protocol #SponsorProtocol Title
NCT02296125

AstraZeneca
D5160C00007, 2014-002694-11, U1111-1160-2242		A Phase III, Double-blind, Randomized Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer
NCT02367781
Hoffmann-La Roche
GO29537, 2014-003206-32		A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
NCT02367794

Hoffmann-La Roche
GO29437		A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3208A in Combination with Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non-small Cell Lung Cancer
NCT02125461


AstraZeneca
D4191C00001		A Phase III Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer
NCT02477826Bristol-Myers Squibb
CA209-227, 2014-003630-23		An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, Versus Platinum Doublet Chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
 Advanced lung cancer treatment is rapidly evolving. We now know that many lung cancers are ‘driven’ by specific mutations carried by the malignant cells. These ‘driver’ mutations can be targeted by specific medications such as erlotinib and gefitinib (for EGFR mutations), and crizotinib (for ALK rearrangements) and are more effective than chemotherapy. Northwest Georgia Oncology Centers is currently conducting trials of ‘Third Generation’ EGFR and ALK inhibitors, which may offer an improved efficacy profile over the original medications.Non-Small Cell Lung Cancer (NSCLC) without an identifiable driver mutation is now the subject of investigation with the novel PD-1/ PDL-1 inhibitor immunotherapies. Nivolumab (Opdivo(r)) was recently approved for the second line treatment of squamous cell NSCLC. We are now conducting multiple trials of PD-1/ PDL-1 inhibitors in other types of NSCLC, after radiation therapy, and combined with chemotherapy.
Protocol #SponsorProtocol Title
NCT0220757


CytRxA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
 The treatment of advanced lung cancer is rapidly evolving. We now know that many lung cancers are ‘driven’ by specific mutations carried by the malignant cells. These ‘driver’ mutations can be targeted by specific medications such as erlotinib and gefitinib (for EGFR mutations), and crizotinib (for ALK rearrangements) and are more effective than chemotherapy. Northwest Georgia Oncology Centers is currently conducting trials of ‘Third Generation’ EGFR and ALK inhibitors, which may offer an improved efficacy profile over the original medications.Non-Small Cell Lung Cancer (NSCLC) without an identifiable driver mutation is now the subject of investigation with the novel PD-1/ PDL-1 inhibitor immunotherapies. Nivolumab (Opdivo(r)) was recently approved for the second line treatment of squamous cell NSCLC. We are now conducting multiple trials of PD-1/ PDL-1 inhibitors in other types of NSCLC, after radiation therapy, and combined with chemotherapy.